

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

A wholly-owned Chinese subsidiary of BeOne Medicines Ltd. (the “**Company**”) recently received a notice from the competent local tax authority and agreed to make certain adjustments to previously filed tax returns, which will result in an income tax payment (including late payment surcharges) of approximately RMB446 million. The Company will make such payment in a timely manner. No administrative penalty is involved in this tax matter.

This matter does not constitute any prior period accounting error and does not involve any retrospective restatement of the Company’s historical financial information. The income tax expense is expected to be recognized in the Company’s financial statements for fiscal year 2026. The actual impact on the Company’s net income attributable to shareholders of the Company for 2026 is subject to the Company’s audited financial statements for the fiscal year ending December 31, 2026.

This matter will not have material adverse impact on the Company’s financial condition, long-term operating capabilities, or normal business operations.

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, June 26, 2026

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.